Infex Therapeutics Ltd

The UK R&D Centre for Amtimicrobial Resistance

Established in May 2016, the AMR Centre is a key part of the UK’s response to the global threat from Antimicrobial Resistance. Bases at Alderley Park, the AMR Centre is a joint private-public initiative to support/accelerate the development of new antibiotics and diagnostics through a fully integrated development capability, offering translational R&D from pre-clinical hits through to clinical proof of concept. Our mission is to ensure that all new, novel and needed antimicrobial drugs and diagnostics can get to market in the shortest possible time. We have developed a partnering model to support this aim. It will progress research through a clinical trial quickly so that treatments can be brought to market and the threat of antimicrobial resistance can be significantly reduced.

• Small molecules